Evonik markets new advanced technology for sustainable pharmaceutical production

An innovative green technology that enables the large-scale synthesis of active pharmaceutical ingredients in water.

  • Evonik now offers ‘Chemistry in Water’, to enable classical organic reactions to be performed in water
  • New technology allows drug manufacturing with improved environmental footprint
  • Evonik is collaborating with Professor Bruce Lipshutz, University of California, Santa Barbara


Essen, Germany.  From June 2021, Evonik offers an innovative green technology that enables the large-scale synthesis of active pharmaceutical ingredients in water.  This technology has the potential to significantly reduce the environmental footprint of drug manufacturing by minimizing the need for large volumes of solvent and helping to simplify processes.


‘Chemistry in Water’ or ‘micellar chemistry’ uses surfactants which form microscopic spheres in water, called micelles.  These function as nanoreactors and enable organic reactions, which are generally run in organic solvents, to be performed in water.


The successful integration of micellar chemistry into Evonik’s CDMO portfolio follows a collaboration with pioneering organic chemist Professor Bruce Lipshutz of the University of California, Santa Barbara.


“Improving the environmental footprint for the synthesis of active pharmaceutical ingredients is critically important for the sustainability of drug manufacturing going forward.  It is a great pleasure to work with technology pioneer Professor Bruce Lipshutz and bring Chemistry in Water to commercial scale,” says Dr. Stefan Randl, head of Research, Development & Innovation for the Health Care business line of Evonik.


“After many years developing micellar chemistry, it is immensely rewarding to see industry applying and further developing its potential.  I am confident that working together with Evonik, as the first adopter for CDMO purposes, will pave the way for wider application in industry and overall, more sustainable chemistry,” says Bruce Lipshutz.


Apart from reducing the need for organic solvents in organic reactions, micellar chemistry also has the potential to generate higher yields and increase selectivity under mild conditions.  Significant reduction of catalyst loading, energy consumption and waste production has been achieved using this approach for many reaction processes.


Evonik’s Health Care business is part of the life sciences division Nutrition & Care, for which sustainability is the guiding business principle.  Evonik Health Care is one of the world’s largest CDMO (Contract Development and Manufacturing Organization) with capabilities to manufacture customized APIs/HPAPIs.


To address specific customer needs, Evonik has established a broad portfolio of advanced technologies which can be combined to support multi-step API synthesis.  These technologies include continuous processing, fermentation, highly pure PEGs and mPEGs, transition metal catalysis, biocatalysis, organometallic/cryogenic chemistry, and from now on Chemistry in Water.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.Asia Pacific is a strong driving force of the global economy and an important source of innovation.  Consequently Evonik endeavors to further grow its business in the region.  Sales reached €2.84 billion in 2020 and the company employs over 5,000 people at more than 50 production sites in Asia Pacific.  In Taiwan, we now employ over 200 employees which including 1 office based in Taipei and 1 production site based in Taoyuan.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties.  Actual results or developments may vary, depending on changes in the operating environment.  Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.